729 related articles for article (PubMed ID: 26782683)
1. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
[TBL] [Abstract][Full Text] [Related]
2. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials.
Liu Z; Zhang M; Shen Z; Ke J; Zhang D; Yin F
PLoS One; 2020; 15(12):e0243851. PubMed ID: 33326444
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
Zhou J; Ma X; Wang T; Zhai S
Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
[TBL] [Abstract][Full Text] [Related]
7. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials.
Jin YZ; Lee JH; Xu B; Cho M
BMC Musculoskelet Disord; 2019 Aug; 20(1):399. PubMed ID: 31472671
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Nicolopoulos K; Moshi MR; Stringer D; Ma N; Jenal M; Vreugdenburg T
Arch Osteoporos; 2023 Jan; 18(1):18. PubMed ID: 36624318
[TBL] [Abstract][Full Text] [Related]
9. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Chen LX; Zhou ZR; Li YL; Ning GZ; Zhang TS; Zhang D; Feng SQ
PLoS One; 2015; 10(5):e0128032. PubMed ID: 26010450
[TBL] [Abstract][Full Text] [Related]
11. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Boonen S; Laan RF; Barton IP; Watts NB
Osteoporos Int; 2005 Oct; 16(10):1291-8. PubMed ID: 15986101
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis.
Sanderson J; Martyn-St James M; Stevens J; Goka E; Wong R; Campbell F; Selby P; Gittoes N; Davis S
Bone; 2016 Aug; 89():52-58. PubMed ID: 27262775
[TBL] [Abstract][Full Text] [Related]
13. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.
Reginster J-; Bianic F; Campbell R; Martin M; Williams SA; Fitzpatrick LA
Osteoporos Int; 2019 Jul; 30(7):1465-1473. PubMed ID: 30953114
[TBL] [Abstract][Full Text] [Related]
14. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
15. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
17. Network Meta-Analysis of Pharmacological Agents for Osteoporosis Treatment and Fracture Prevention.
Yang XC; Deng ZH; Wen T; Luo W; Xiao WF; Zhao RB; Li YS
Cell Physiol Biochem; 2016; 40(3-4):781-795. PubMed ID: 27915335
[TBL] [Abstract][Full Text] [Related]
18. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Li P; Wu X; Li Y; Huang J
Clin Invest Med; 2022 Sep; 45(3):E14-22. PubMed ID: 36149052
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
Chen L; Wang G; Zheng F; Zhao H; Li H
Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
[TBL] [Abstract][Full Text] [Related]
20. Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.
Wang WY; Chen LH; Ma WJ; You RX
Eur Rev Med Pharmacol Sci; 2023 Sep; 27(17):8253-8268. PubMed ID: 37750653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
